These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 20585136)

  • 21. Influenza viruses resistant to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.
    Puzelli S; Facchini M; Di Martino A; Fabiani C; Lackenby A; Zambon M; Donatelli I
    Antiviral Res; 2011 Jun; 90(3):205-12. PubMed ID: 21514326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Replacement of neuraminidase inhibitor-susceptible influenza A(H1N1) with resistant phenotype in 2008 and circulation of susceptible influenza A and B viruses during 2009-2013, South Africa.
    Treurnicht FK; Buys A; Tempia S; Seleka M; Cohen AL; Walaza S; Glass AJ; Rossouw I; McAnerney J; Blumberg L; Cohen C; Venter M
    Influenza Other Respir Viruses; 2019 Jan; 13(1):54-63. PubMed ID: 30218485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.
    Monto AS; McKimm-Breschkin JL; Macken C; Hampson AW; Hay A; Klimov A; Tashiro M; Webster RG; Aymard M; Hayden FG; Zambon M
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2395-402. PubMed ID: 16801417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.
    Okomo-Adhiambo M; Sleeman K; Ballenger K; Nguyen HT; Mishin VP; Sheu TG; Smagala J; Li Y; Klimov AI; Gubareva LV
    Viruses; 2010 Oct; 2(10):2269-2289. PubMed ID: 21994620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
    Huang W; Cheng Y; Li X; Tan M; Wei H; Zhao X; Xiao N; Dong J; Wang D
    J Infect Chemother; 2018 Sep; 24(9):729-733. PubMed ID: 29866491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses.
    Barrett S; Mohr PG; Schmidt PM; McKimm-Breschkin JL
    PLoS One; 2011; 6(8):e23627. PubMed ID: 21858186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors.
    Okomo-Adhiambo M; Sheu TG; Gubareva LV
    Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):44-9. PubMed ID: 23279896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuraminidase inhibitors for critically ill children with influenza.
    Louie JK; Yang S; Samuel MC; Uyeki TM; Schechter R
    Pediatrics; 2013 Dec; 132(6):e1539-45. PubMed ID: 24276847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
    Hurt AC; Okomo-Adhiambo M; Gubareva LV
    Methods Mol Biol; 2012; 865():115-25. PubMed ID: 22528156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013.
    Takemoto Y; Asai T; Ikezoe I; Yano T; Ichikawa M; Miyagawa S; Matsumoto J
    Chemotherapy; 2013; 59(5):373-8. PubMed ID: 24821568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. E119D Neuraminidase Mutation Conferring Pan-Resistance to Neuraminidase Inhibitors in an A(H1N1)pdm09 Isolate From a Stem-Cell Transplant Recipient.
    L'Huillier AG; Abed Y; Petty TJ; Cordey S; Thomas Y; Bouhy X; Schibler M; Simon A; Chalandon Y; van Delden C; Zdobnov E; Boquete-Suter P; Boivin G; Kaiser L
    J Infect Dis; 2015 Dec; 212(11):1726-34. PubMed ID: 25985905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
    Fage C; Tu V; Carbonneau J; Abed Y; Boivin G
    Antivir Ther; 2017; 22(8):711-716. PubMed ID: 29082897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea.
    Kim HM; Lee N; Kim MS; Kang C; Chung YS
    Virol J; 2020 Jul; 17(1):94. PubMed ID: 32631440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
    Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
    Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness.
    Kwon JJ; Choi WS; Jeong JH; Kim EH; Lee OJ; Yoon SW; Hwang J; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
    J Gen Virol; 2018 Mar; 99(3):292-302. PubMed ID: 29493493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
    Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
    J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular pathway of influenza pan-neuraminidase inhibitor resistance in an immunocompromised patient.
    Abed Y; Schibler M; Checkmahomed L; Carbonneau J; Venable MC; Fage C; Giannotti F; Goncalves AR; Kaiser L; Boivin G
    Antivir Ther; 2019; 24(8):581-587. PubMed ID: 32031540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.